CR Pharma IPO - Valuation Is Rich at the Top End

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

China Resources Pharmaceutical / Equity Capital Markets

<p>China Resources Pharmaceutical Group has filed an Application Proof to list on the HKEX this year, possibly in the current quarter. Our initial Insight <a href="https://www.smartkarma.com/insights/cr-pharma-listing-part-1" target="_blank" data-smartkarma-citation="insights:5268">CR Pharma Listing: Part 1</a> discussed the manufacturing segment. This Insight will discuss the distribution and retail segments. Part 3 will discuss the R&amp;D pipeline and other remaining topics of interest. We will re-visit the subject once more details of the listing are available.</p><p> </p>

China Resources Pharmaceutical Group has filed an Application Proof to list on the HKEX this year, possibly in the current quarter. Our initial Insight CR Pharma Listing: Part 1 discussed the manufacturing segment. This Insight will discuss the distribution and retail segments. Part 3 will discuss the R&amp;D pipeline and other remaining topics of interest. We will re-visit the subject once more details of the listing are available. 

Shanghai Pharmaceuticals Holding (2607 HK)

Guangzhou Baiyunshan Pharmaceutical Holdings (874 HK)

Guangzhou Baiyunshan Pharmaceutical Holdings

China Resources Sanjiu Medical & Pharma (000999 CH)

China Resources Dubl Crne Phrmctl (600062 CH)

China Resources Pharmaceutical

CR Pharma Listing: Part 2